Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2014-01-23 | BL-8040 | BiolineRx (Israel) | stem cell mobilization |
Granting of the orphan status in the US |
2015-02-20 | riociguat | Bayer (Germany) | pulmonary arterial hypertension (PAH) |
Granting of a Market Authorisation in Japan |
2014-01-27 | riociguat | Bayer (Germany) | inoperable chronic thromboembolic pulmonary hypertension (CTEPH) |
Granting of a Market Authorisation in the EU |
2015-11-30 | follitropin alfa (biosimilar) | FINOX Biotech (Switzerland) | fertility disorders |
Granting of a Market Authorisation in Australia |
2014-01-27 | masitinib | AB Science (France) | advanced inoperable pancreatic cancer |
Granting of a patent |
2014-01-30 | QIAsymphony RGQ MDx workflow | Qiagen (The Netherlands) | healthcare-associated infections including C. difficile infections |
Submission of a Market Application in the US |
2015-08-28 | eltrombopag | Novartis (Switzerland) GSK (UK) Ligand Pharmaceuticals (USA - CA) | treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy |
Granting of a Market Authorisation in the EU |
2014-02-04 | Botulinum toxin type A | Allergan (USA) | ankle disability due to ower limb spasticity in adults who have had a stroke |
Granting of a patent |
2014-02-04 | brentuximab vedotin | Seattle Genetics (USA - MA) | diffuse large B-cell lymphoma | Granting of the orphan status in the EU |
2014-02-04 | recombinant DNA plasmid | Scancell (UK) | stage IIb, IIc, III and IV melanoma |
Granting of a patent |
2014-02-04 | paquinimod | Active Biotech (Sweden) | systemic sclerosis | |
2014-01-10 | factor VIII mimetic bispecific antibody | Genentech, a member of Roche Group (USA - CA - Switzerland) | hemophilia A |
Granting of the orphan status in the US |
2014-02-12 | proprietary inhibitors of the intracellular enzyme TDO2 | iTeos Therapeutics (Belgium) | Granting of a patent | |
2016-02-16 | ledipasvir/sofosbuvir fixed-dose combination | Gilead Sciences (USA -CA) | chronic hepatitis C genotypes 1, 4, 5 and 6, HCV/HIV-1 coinfection, HCV genotype 1 and 4 liver transplant recipients, and genotype 1-infected patients with decompensated cirrhosis chronic hepatitis C (CHC) in adults and in adolescents aged 12 to < 18 years | Positive opinion for the granting of a Market Authorisation in the EU |
2014-02-18 | GFT505 | Genfit (France) | NASH (non-alcoholic steatohepatitis) | Granting of a Fast Track status |
2014-02-20 | rosuvastatine | AstraZeneca (UK) | pediatric homozygous familial hypercholesterolemia | |
2014-02-20 | caprine hyperimmune serum against HIV lysate | Daval International (UK) | ||
2014-02-23 | cysteamine bitartrate | Raptor Pharmaceuticals Europe | pancreatic cancer |
Granting of the orphan status in the EU |
2014-05-08 | ex-vivo-cultured human mesenchymal stromal cells | iCell Science (Sweden) | prevention of graft rejection following solid organ transplantation |
Granting of the orphan status in the US |
2014-02-23 | recombinant human alpha-glucosidase conjugated with multiple copies of synthetic bismannose-6-phosphate-tetra-mannose glycan | Genzyme (USA - MA), a Sanofi company (France) | glycogen storage disease type II (Pompe's disease) |
Granting of the orphan status in the EU |
© 2024 Biopharmanalyses - Powered by Samacom+